Serine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Serine: From No Established Indication to Familial Visceral Myopathy (Preliminary Signal)
One-Sentence Summary
Serine (L-serine, DrugBank DB00133) has no recorded approved indication and is not currently marketed in South Africa. TxGNN’s knowledge graph predicts a very strong association (99.99%) with familial visceral myopathy, but this ranking is supported by zero clinical trials and zero publications — it is a model-only signal with no verifiable clinical or mechanistic basis at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded — Serine has no approved indication on file and is not marketed in South Africa |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Serine. Based on general pharmacology knowledge, L-serine is a non-essential amino acid involved in one-carbon metabolism and phospholipid/nucleotide biosynthesis, but no established therapeutic role in gastrointestinal or visceral smooth muscle disease has been documented in the available data.
The TxGNN knowledge-graph association score for familial visceral myopathy is very high (0.9999, rank 104), which on its own might suggest a strong latent signal. However, this evidence pack found no supporting clinical trials or literature whatsoever for this drug–disease pair. Because Serine’s original indication and mechanism of action are both unrecorded, there is no independent basis — pharmacological or clinical — to corroborate or explain why this association exists. The prediction should be treated strictly as a graph-model hypothesis pending mechanistic and clinical validation.
It is also worth noting that this Serine evidence pack examined 10 TxGNN-predicted indications in total. For the handful of lower-ranked candidates that did return trial or literature hits (e.g., intestinal obstruction, angle-closure glaucoma), manual review found the retrieved records were overwhelmingly keyword-collision artifacts — matches on “serine protease” or “serine/threonine kinase” gene names rather than evidence about L-serine as a therapeutic agent. This reinforces that, across the full candidate set, no genuine repurposing evidence for Serine currently exists.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Serine is not currently registered with SAHPRA and has no marketed products in South Africa (0 licenses on file). No market information is available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: safety/label data (warnings and contraindications) for this drug is currently a blocking data gap — without it, a formal safety pre-assessment cannot be completed.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but it is unsupported by any clinical trial, publication, mechanism-of-action data, or existing market/regulatory record. Combined with a blocking safety data gap, there is no basis to advance this candidate beyond a research hypothesis.
To proceed, the following is needed:
- Mechanism of action (MOA) data for Serine (query DrugBank/primary literature)
- SAHPRA-equivalent or international product labeling (warnings, contraindications) to close the blocking safety data gap
- Preclinical or mechanistic studies linking L-serine to visceral smooth muscle/myopathic pathology
- Dedicated clinical trial or observational evidence specific to familial visceral myopathy (current literature hits for other candidate indications were confounded by “serine protease/kinase” naming collisions and should not be treated as supporting evidence)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.